Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

s compared to placebo.

"The results of the MERLIN TIMI-36 study confirm that ranolazine is a safe and effective anti-ischemic drug that also has favorable effects on arrhythmia and HbA1c," Morrow said. "The reduction in HbA1c observed with ranolazine in the MERLIN TIMI-36 study is especially striking because the effects were observed on top of multiple other anti-diabetic drugs used as part of standard therapy."

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina. In September 2007, the Company submitted a supplemental new drug application to the FDA seeking a new indication for first line angina and a significant reduction in cautionary language.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERL
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... DALLAS, April 4, 2008 Data from five ... presented at the National Kidney,Foundation (NKF) 2008 Spring ... utilization studies involve PROCRIT(R) (Epoetin alfa)., The ... and,costs of PROCRIT (EPO) and darbepoetin alfa (DARB), ...
... Previously-Stated Guidance Remains Unchanged, PRINCETON, N.J., ... MEDX ) today issued the following statement ... that it was discontinuing its Phase 3 ... anti-CTLA-4,antibody (tremelimumab) compared to chemotherapy in patients ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County Bar Association ... 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law ... of investigating these types of cases. , Each year, New York State residents ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a ... features the latest and coolest technology products available to consumers. Amanda Forstrom, a technology ... these selfie sticks are great for documenting memories. , Almost every smartphone has an ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... RI (PRWEB) , ... July 02, 2015 , ... Many ... safety in mind. That’s why Amica Insurance is sharing some tips to ... Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related injuries ...
(Date:7/2/2015)... ... July 02, 2015 , ... Get ready to hit the ... Since the socks were first introduced, they have rapidly been gaining attention among ... four new, fun shades including: blue, lime, pink and red. , Utilizing ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2
... N.J., Nov. 2 comScore, Inc. (Nasdaq: ... world, and ImpactRx, a pharmaceutical insights company, today announced ... the only digital measurement solution that connects physicians, online ... This solution is carefully designed to comply with health ...
... to develop the disorder, study finds, , MONDAY, Nov. 2 ... by a strong urge to move the legs, is much ... U.S. study has found. , Researchers interviewed 190 people being ... those who were black, compared with 36 percent of those ...
... developing the brain disease, study finds , MONDAY, Nov. ... Alzheimer,s disease are at increased risk for high blood ... -- all of which may be associated with later ... a study by researchers in the Netherlands who compared ...
... PNAS provides a comprehensive comparative functional anatomy study in ... networks preserved across evolution. An international collaboration co-led ... York City examined patterns of connectivity to show that ... is actually divided into four distinct functional regions. ...
... walkability (degree of ease for walking) with local levels ... be good for walking, but have poor air quality. ... faculty member Julian Marshall and University of British Columbia ... highlight the need for urban design to consider both ...
... Richard L. ... ... Chief Executive Officer of Jackson Healthcare ®, Richard L. Jackson, will present at the ... Jackson will be part of a discussion panel addressing the tort reform debate and control ...
Cached Medicine News:Health News:comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution 2Health News:comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution 3Health News:Restless Legs May Vary by Race and Gender 2Health News:High Blood Pressure Likely in Alzheimer's Offspring 2Health News:Researchers discover links between city walkability and air pollution exposure 2Health News:Researchers discover links between city walkability and air pollution exposure 3Health News:CEO of Jackson Healthcare to Speak at Physicians' Council for Responsible Reform Upcoming Strategy Meeting 2Health News:CEO of Jackson Healthcare to Speak at Physicians' Council for Responsible Reform Upcoming Strategy Meeting 3
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: